Get the Stockscreener App
5.72
4.00%
0.22
After Hours:
5.72
Lexeo Therapeutics Inc stock is traded at $5.72, with a volume of 719.34K.
It is up +4.00% in the last 24 hours and down -16.98% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$5.50
Open:
$5.67
24h Volume:
719.34K
Relative Volume:
0.63
Market Cap:
$417.49M
Revenue:
$531.00K
Net Income/Loss:
$-104.97M
P/E Ratio:
-2.1172
EPS:
-2.7017
Net Cash Flow:
$-107.19M
1W Performance:
-0.61%
1M Performance:
-16.98%
6M Performance:
-12.00%
1Y Performance:
+28.83%
1-Day Range:
$5.67
$5.96
1-Week Range:
$5.22
$5.96
52-Week Range:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
5.72 | 401.43M | 531.00K | -104.97M | -107.19M | -2.7017 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Raymond James | Strong Buy |
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Wall Street Recap: Is Lexeo Therapeutics Inc. subject to activist investor interestTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Hedge Fund Moves: Does Lexeo Therapeutics Inc have declining or rising EPSMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-03-22 00:04:32 - baoquankhu1.vn
Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation - MSN
Is Lexeo Therapeutics Inc forming a bullish divergence2026 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan
Signal Recap: Can Lexeo Therapeutics Inc ride the EV waveMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday - MarketBeat
LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
LXEO Stock Chart | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4%What's Next? - MarketBeat
Sectors Review: Is Lexeo Therapeutics Inc. subject to activist investor interestWeekly Trade Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Lexeo Therapeutics Inc a cyclical or defensive stockMarket Volume Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Published on: 2026-03-07 09:09:20 - baoquankhu1.vn
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - The Manila Times
Genetic medicine firm Lexeo to stream Leerink conference chat - Stock Titan
Nasdaq Moves: Can Lexeo Therapeutics Inc ride the EV waveRate Cut & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference - MarketBeat
Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
LXEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Update: Is Lexeo Therapeutics Inc forming a bullish divergenceProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Profit Review: Is Lexeo Therapeutics Inc forming a bullish divergenceShare Buyback & Risk Controlled Stock Alerts - baoquankhu1.vn
Narinder Pal Bhalla Net Worth (2026) - GuruFocus
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $64,903.74 in Stock - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) COO Sells $19,302.40 in Stock - Defense World
Will Lexeo Therapeutics Inc. outperform its industry peersEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
Top Brass at Biotech Player Quietly Cash Out in Latest Insider Move - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeutics Inc. - GuruFocus
Lexeo Therapeutics (LXEO) CEO sells 10,173 shares in tax-related trade - Stock Titan
LXEO (NASDAQ: LXEO) affiliate plans sale of 4,867 vested shares - Stock Titan
LXEO (NASDAQ: LXEO) Form 144 reports 3,861 shares tied to vesting - Stock Titan
LXEO Should I Buy - Intellectia AI
Citadel discloses 7.4% Lexeo Therapeutics (LXEO) ownership in 13G/A - Stock Titan
BioAgilytix Labs, Inc Receives FDA Breakthrough Device Designation for Anti-AAV Antibody Assay - The Courier-Journal
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-16 16:57:11 - baoquankhu1.vn
Is Lexeo Therapeutics Inc. still a buy after recent gainsJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - mfd.ru
Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit - MarketBeat
A | Does Lexeo Therapeutics, Inc. have declining or rising EPSPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru
Page not foundAirwhon - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2%Time to Sell? - MarketBeat
Will Lexeo Therapeutics Inc. announce a stock splitJuly 2025 Spike Watch & Smart Allocation Stock Reports - mfd.ru
Volatility Watch: Is Lexeo Therapeutics Inc backed by strong institutional buyingPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Lexeo Therapeutics Announces Head of Research Transition - The Globe and Mail
Lexeo Therapeutics (LXEO) CFO receives RSUs and 226,665-share stock option - Stock Titan
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - 富途牛牛
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):